DE69913332D1 - Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie - Google Patents

Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie

Info

Publication number
DE69913332D1
DE69913332D1 DE69913332T DE69913332T DE69913332D1 DE 69913332 D1 DE69913332 D1 DE 69913332D1 DE 69913332 T DE69913332 T DE 69913332T DE 69913332 T DE69913332 T DE 69913332T DE 69913332 D1 DE69913332 D1 DE 69913332D1
Authority
DE
Germany
Prior art keywords
tetralone
pure
enantiomered
producing
optically enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69913332T
Other languages
English (en)
Other versions
DE69913332T2 (de
Inventor
Oliver Dapremont
Fiona Geiser
Tong Zhang
S Guhan
M Guinn
J Quallich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE69913332D1 publication Critical patent/DE69913332D1/de
Publication of DE69913332T2 publication Critical patent/DE69913332T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/78—Separation; Purification; Stabilisation; Use of additives
    • C07C45/79—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69913332T 1998-05-01 1999-04-27 Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie Expired - Fee Related DE69913332T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8385198P 1998-05-01 1998-05-01
US83851P 1998-05-01
PCT/US1999/009037 WO1999057089A1 (en) 1998-05-01 1999-04-27 Process for the production of enantiomerically pure or optically enriched sertraline-tetralone using continuous chromatography

Publications (2)

Publication Number Publication Date
DE69913332D1 true DE69913332D1 (de) 2004-01-15
DE69913332T2 DE69913332T2 (de) 2004-05-27

Family

ID=22181106

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69913332T Expired - Fee Related DE69913332T2 (de) 1998-05-01 1999-04-27 Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie

Country Status (9)

Country Link
US (1) US6444854B1 (de)
EP (1) EP1073618B1 (de)
AT (1) ATE255555T1 (de)
CA (1) CA2342201C (de)
DE (1) DE69913332T2 (de)
DK (1) DK1073618T3 (de)
ES (1) ES2211080T3 (de)
PT (1) PT1073618E (de)
WO (1) WO1999057089A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
US6458955B1 (en) 1994-12-16 2002-10-01 Uop Llc Process for preparation of pharmaceutically desired enantiomers
FR2810978B1 (fr) * 2000-06-29 2004-05-28 Chiralsep Sarl Procede de dedoublement de l'intermediaire tetralone de la sertraline
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
US6683220B2 (en) * 2001-10-31 2004-01-27 Pfizer, Inc. Process for the preparation of optically pure or enriched racemic tetralone
US20060128955A1 (en) * 2003-05-09 2006-06-15 Vela Pharmaceuticals, Inc. Method of isolating (R)-tofisopam
US7772240B2 (en) * 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
MX2007009816A (es) * 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
FR2898283B1 (fr) 2006-03-08 2011-07-15 Novasep Procede et dispositif de separation de fractions d'un melange.
WO2008088830A2 (en) * 2007-01-16 2008-07-24 Evolved Nanomaterial Sciences, Inc. Chiral separating agents with active support
US7776740B2 (en) * 2008-01-22 2010-08-17 Tokyo Electron Limited Method for integrating selective low-temperature ruthenium deposition into copper metallization of a semiconductor device
AU2009243813B2 (en) * 2008-05-07 2014-05-29 H. Lundbeck A/S Method for treating cognitive deficits
KR20110081176A (ko) * 2008-10-03 2011-07-13 하. 룬드벡 아크티에셀스카브 경구용 제형물
CN104122342A (zh) * 2014-07-04 2014-10-29 惠州市莱佛士制药技术有限公司 一种盐酸舍曲林中间体(±)-Tetralone及其手性色谱拆分方法
US9127136B1 (en) 2014-07-18 2015-09-08 Sabic Global Technologies B.V. Purification of monomer from recycle polyesters
CN104826619A (zh) * 2015-05-08 2015-08-12 广州研创生物技术发展有限公司 键合3,5-二甲基苯氨基甲酰化β-环糊精手性固定相在手性分析和/或分离盐酸舍曲林中间体(±)-Tetralone的应用
CN106268657A (zh) * 2015-05-14 2017-01-04 株式会社大赛璐 光学异构体用分离剂
EP3566769B1 (de) 2018-05-07 2023-07-26 Yf1 Simulationsmethode und -vorrichtung einer industrieanlage für die nutzung eines chemischen oder biochemischen verfahrens
EP3786733B1 (de) 2019-08-29 2023-04-12 Yf1 System und verfahren für die simulation eines chemischen oder biochemischen verfahrens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3010816B2 (ja) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法
EP0577079B1 (de) * 1992-06-30 1999-12-01 Daicel Chemical Industries, Ltd. Trennsystem mit simuliertem Fliessbett
US5466880A (en) * 1992-09-15 1995-11-14 Pfizer Inc. Process for preparing ketone enantiomer
US5288916A (en) 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
US5630943A (en) * 1995-11-30 1997-05-20 Merck Patent Gesellschaft Mit Beschrankter Haftung Discontinuous countercurrent chromatographic process and apparatus

Also Published As

Publication number Publication date
ATE255555T1 (de) 2003-12-15
DE69913332T2 (de) 2004-05-27
ES2211080T3 (es) 2004-07-01
CA2342201A1 (en) 1999-11-11
DK1073618T3 (da) 2004-03-15
CA2342201C (en) 2005-08-09
WO1999057089A1 (en) 1999-11-11
EP1073618A1 (de) 2001-02-07
EP1073618B1 (de) 2003-12-03
US6444854B1 (en) 2002-09-03
PT1073618E (pt) 2004-03-31

Similar Documents

Publication Publication Date Title
DE69913332D1 (de) Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie
ES2141632A1 (es) Procedimiento para la obtencion de un enantiomero opticamente puro de formoterol.
BR9507212A (pt) Processo para estrair uma composiçao compreendendo um composto biologicamente ativo ou um precursor do mesmo e um composto ou uma composiçao de matéria de uma matéria-prima e um produto natural de um material vegetal composiçao produto natural e óleo aromâtico ou aromatizado
DE60331312D1 (de) Behandlung von einer cellulosehaltigen mischung mit einem reduzierenden mittel
FR2802329B1 (fr) Procede de traitement d'au moins un flux binaire audio code organise sous la forme de trames
IS7064A (is) Aðferð til framleiðslu á essítalóprami
DE59000751D1 (de) Verfahren zur herstellung von polyaethylenfaeden durch schnellspinnen von ultrahochmolekularem polyaethylen.
DE59704288D1 (de) Verfahren zur Herstellung von Alpha,Omega-C4- bis C20-Alkenolen
DE59912722D1 (de) Kontinuierliches verfahren zur trennung von stoffen nach molekülgrösse
ATE109209T1 (de) Verfahren zur herstellung von xylose.
DE69007800D1 (de) Verfahren zur fermentativen Herstellung von L-Arginin.
CA2119674A1 (en) Enantiomeric Resolution of 4-(3,4-Dichlorophenyl)-3,4-Dihydro-1(2H)-Naphthalenone
DE60326212D1 (de) Verfahren zur herstellung einer katalysatorkomponente basierend auf einem diether
ATE159706T1 (de) Verfahren zur herstellung von chiralen tetralonen
ATE246173T1 (de) Verfahren zur herstellung von n-methyl-pyrrolidon
PT1349828E (pt) Processo para a preparacao de isomeros de salutamol
DE60220312D1 (de) Verfahren zur herstellung und fraktionierung von gelbildenden und nicht gelbildenden carrageenanen aus zweikomponentigem tang
AR037046A1 (es) Un procedimiento para la preparacion de tetralona racemica opticamente pura o enriquecida
DE59105474D1 (de) Verfahren zur herstellung von zeolith-granulaten.
ATE221288T1 (de) System zum verwalten von anwendungsprogrammen mit einem variablen verwaltungsbefehlssatz
KR910002745A (ko) 드로프로피진의 광학적 분할방법
ATE347609T1 (de) Enzymatisches verfahren zur herstellung von organofluorverbindungen
ATE326444T1 (de) Verfahren zur herstellung einer enantiomerenangereicherten schiff base
RU2006118316A (ru) Новый способ получения оптически чистого производного 2-морфинола
JP2007510630A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee